Citations

Clear

8 citation(s) found for "Scott, Eric".

Correction: Endoluminal radiofrequency ablation with stenting versus stenting alone in patients with malignant biliary obstruction: a meta-analysis of randomized trials
Ramai, Daryl , Maida, Marcello , Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , DuBroff, Jason, Ko, Christopher , Morris, John D., Khashab, Mouen A., Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Mangiavillano, Benedetto , Smith, Eric R. , Spadaccini, Marco , Previtera, Melissa J. , Bhandari, Peter , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Khashab, Mouen A.

Mayo Clinic

Endoscopy | July 28, 2025 | Volume: 57 | Issue: 09 | Pages: C11-C11

10.1055/a-2664-6391 | PMID 40720957 Get It

Endoluminal radiofrequency ablation with stenting versus stenting alone in patients with malignant biliary obstruction: a meta-analysis of randomized trials
Ramai, Daryl , Maida, Marcello , Smith, Eric , Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , DuBroff, Jason, Ko, Christopher , Morris, John D., Marasco, Giovanni , Crinò, Stefano Francesco , Khashab, Mouen A., Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Mangiavillano, Benedetto , Wang, Yichen , Spadaccini, Marco , Previtera, Melissa J. , Bhandari, Peter , Facciorusso, Antonio , Khashab, Mouen A.

Mayo Clinic

Endoscopy | August 2, 2024 | Volume: 57 | Issue: 03 | Pages: 272-281

10.1055/a-2378-9533 | PMID 39094769 Get It

AbstractEndoluminal radiofrequency ablation (RFA) is a palliative treatment for patients suffering from malignant biliary obstruction (MBO). We aimed to conduct a meta-analysis to evaluate the impact of RFA on stent patency, patient survival, and adverse events.Major databases were searched through December 2023 for patients who had undergone stenting with or without RFA for extrahepatic MBO. A random-effects model was used for analysis, with results expressed as relative risk ratios (RRs) with 95%CIs.Nine RCTs involving 750 subjects with MBO (374 RFA plus stent vs. 376 stent only) were included. Meta-analysis revealed similar risks of stent patency at 3 months (RR 1.01, 95%CI 0.92–1.11; I 2 = 4%) for RFA plus stenting vs. stent only. Meta-analysis showed improved survival at 6 months (RR 0.84, 95%CI 0.73–0.96; I 2 = 21%; P = 0.01) for RFA plus stenting vs. stent only. Subgroup analysis comparing plastic vs. uncovered metal stents showed that stent patency was unaffected at 3 months (RR 1.06, 95%CI 0.91–1.23; I 2 = 17%). Subgroup analysis showed that patients with cholangiocarcinoma experienced an overall survival benefit with RFA plus stenting vs. stenting alone (P < 0.001); however, stent patency remained unaffected (P = 0.08). An increased incidence of cholecystitis was noted with RFA plus stenting vs. stenting alone (5.1% [95%CI 3.1%–7.8%] vs. 0.3% [95%CI 0.01%–1.5%], respectively).Combining endoluminal RFA and stenting may improve overall survival in patients with MBO. RFA did not significantly impact stent patency.
Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Qin, Kang , Li, Shenduo , Hong, Lingzhi , Padmakumar, Priyadharshini, Waree, Rinsurongkawong, Le, Xiuning , Vokes, Natalie I. , Vaporciyan, Ara A. , Lee, J. Jack , Jaffray, David A. , Altan, Mehmet , Lou, Yanyan , Zhang, Jianjun , Hong, Lingzhi , Le, Xiuning , Lee, J Jack , Zhang, Jianjun , Wang, Kaiwen , Hubert, Shawna Marie , Rai, Kunal , Gibbons, Don L , Heymach, John V. , Woodman, Scott Eric , Chung, Caroline , Vokes, N.

Mayo Clinic

Cancers | February 26, 2024 | Volume: 16 | Issue: 5 | Pages: 935

10.3390/cancers16050935 | PMID 38473297 Get It

Docetaxel +/− ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/− ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/− ramucirumab n=381; platinum/taxane-based regimens n=73). Progression-free survival (PFS) and overall survival (OS) were compared among different subpopulations with different cancer gene mutations and between patients who received docetaxel +/− ramucirumab versus platinum/taxane-based regimens. Among patients who received docetaxel +/− ramucirumab, the top mutated cancer genes included TP53 (n=167), KRAS (n=127), EGFR (n=65), STK11 (n=32), ERBB2 (HER2) (n=26), etc. None of these cancer gene mutations or PD-L1 expression was associated with PFS or OS. Platinum/taxane-based regimens were associated with a significantly longer mQS (13.00 m, 95% Cl: 11.20–14.80 m versus 8.40 m, 95% Cl: 7.12–9.68 m, LogRank P=0.019) than docetaxel +/− ramcirumab. Key prognostic factors including age, histology, and performance status were not different between these two groups. In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/− ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/− ramucirumab in this patient population.
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System
Sparks, Matthew A. , South, Andrew M. , Badley, Andrew D. , Baker‐Smith, Carissa M. , Bozkurt, Biykem , Cattaneo, Roberto , Crowley, Steven D. , Dell’Italia, Louis J. , Ford, Andria L. , Griendling, Kathy K. , Gurley, Susan B. , Nath, Karl A. , Rangaswami, Janani , Taylor, W. Robert , Badley, Andrew D , Baker-Smith, Carissa M , Sparks, Matthew A , Batlle, Daniel , Kasner, Scott Eric , Murray, Joseph A. , Pfeffer, Marc Alan , Garovic, Vesna D.

Mayo Clinic

Hypertension | September 28, 2020 | Volume: 76 | Issue: 5 | Pages: 1350-1367

10.1161/hypertensionaha.120.15948 | PMID 32981369 Get It

The coronavirus disease 2019 (COVID-19) pandemic is associated with significant morbidity and mortality throughout the world, predominantly due to lung and cardiovascular injury. The virus responsible for COVID-19—severe acute respiratory syndrome coronavirus 2—gains entry into host cells via ACE2 (angiotensin-converting enzyme 2). ACE2 is a primary enzyme within the key counter-regulatory pathway of the renin-angiotensin system (RAS), which acts to oppose the actions of Ang (angiotensin) II by generating Ang-(1–7) to reduce inflammation and fibrosis and mitigate end organ damage. As COVID-19 spans multiple organ systems linked to the cardiovascular system, it is imperative to understand clearly how severe acute respiratory syndrome coronavirus 2 may affect the multifaceted RAS. In addition, recognition of the role of ACE2 and the RAS in COVID-19 has renewed interest in its role in the pathophysiology of cardiovascular disease in general. We provide researchers with a framework of best practices in basic and clinical research to interrogate the RAS using appropriate methodology, especially those who are relatively new to the field. This is crucial, as there are many limitations inherent in investigating the RAS in experimental models and in humans. We discuss sound methodological approaches to quantifying enzyme content and activity (ACE, ACE2), peptides (Ang II, Ang-[1–7]), and receptors (types 1 and 2 Ang II receptors, Mas receptor). Our goal is to ensure appropriate research methodology for investigations of the RAS in patients with severe acute respiratory syndrome coronavirus 2 and COVID-19 to ensure optimal rigor and reproducibility and appropriate interpretation of results from these investigations.
Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors
Chow, Eric J. , Cushing‐Haugen, Kara L. , Khera, Nandita , Lee, Stephanie J. , Leisenring, Wendy M. , Mueller, Beth A. , Cheng, Guang‐Shing , Boeckh, Michael, Martin, Paul J. , Schwartz, Stephen M, Baker, K. Scott, Boeckh, Michael , Schwartz, Stephen Mark , Baker, Kevin Scott , Leisenring, Wendy , Chow, Eric J , Lee, Stephanie J

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 35 | Issue: 3 | Pages: 306-313

10.1200/jco.2016.68.8457 | PMID 27870568 Get It

Purpose To compare the risks of serious health outcomes among hematopoietic cell transplantation (HCT) survivors versus a matched population of patients with cancer who did not undergo HCT, where the primary difference may be exposure to HCT. Methods Two-year HCT survivors treated at a comprehensive cancer center from 1992 through 2009 who were Washington State residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were frequency matched by demographic characteristics and underlying cancer diagnosis (as applicable) to non-HCT 2-year cancer survivors, using the state cancer registry (n = 5,455) and the general population (n = 16,340) using driver’s license files. Late outcomes for all three cohorts were ascertained from the state hospital discharge and death registries; subsequent cancers were ascertained from the state cancer registry. Results After median follow-up of 7.1 years, HCT survivors experienced significantly greater rates of hospitalization compared with matched non-HCT cancer survivors (280 v 173 episodes per 1,000 person-years, P < .001) and greater all-cause mortality (hazard ratio [HR], 1.1; 95% CI, 1.01 to 1.3). HCT survivors had more hospitalizations or death with infections (10-year cumulative incidence, 31% v 22%; HR, 1.4; 95% CI, 1.3 to 1.6) and respiratory complications (cumulative incidence, 27% v 20%; HR, 1.4; 95% CI, 1.2 to 1.5). Risks of digestive, skin, and musculoskeletal complications also were greater among HCT versus non-HCT cancer survivors. The two groups had similar risks of circulatory complications and second cancers. Both HCT and non-HCT cancer survivors had significantly greater 10-year cumulative incidences of all major organ-system outcomes versus the general population. Conclusion History of HCT was associated with late morbidity and mortality among cancer survivors. In particular, clinicians who care for HCT survivors should be aware of their high rates of late respiratory and infectious complications.
Stroke After Aortic Valve Surgery
Messé, Steven R. , Acker, Michael A., Fanning, Molly, Giovannetti, Tania , Ratcliffe, Sarah J. , Bilello, Michel , Szeto, Wilson Y. , Bavaria, Joseph E. , Hargrove, W. Clark , Mohler, Emile R., Floyd, Thomas F. , include, The Determining Neurologic Outcomes from Valve Operations (DeNOVO) investigators, Giovanetti, Tania, Matthai, William , Morris, Rohinton J., Pochettino, Alberto , Price, Catherine C. , Selnes, Ola A., Woo, Y. Joseph , Augostides, John G., Cheung, Albert T., Hanson, C. William , Kukafka, Jeremy D., Levy, Warren J., Mickler, Thomas, Milas, Bonnie L., Savino, Joseph S., Vernick, William J., Weiss, Stuart J., Kasner, Scott Eric , include, The Determining Neurologic Outcomes from Valve Operations (DeNOVO) investigators, Desai, Nimesh D. , Horák, Jiří , Kohl, Benjamin

Mayo Clinic

Circulation | April 2, 2014 | Volume: 129 | Issue: 22 | Pages: 2253-2261

10.1161/circulationaha.113.005084 | PMID 24690611 Get It

Background— The incidence and impact of clinical stroke and silent radiographic cerebral infarction complicating open surgical aortic valve replacement (AVR) are poorly characterized. Methods and Results— We performed a prospective cohort study of subjects ≥65 years of age who were undergoing AVR for calcific aortic stenosis. Subjects were evaluated by neurologists preoperatively and postoperatively and underwent postoperative magnetic resonance imaging. Over a 4-year period, 196 subjects were enrolled at 2 sites (mean age, 75.8±6.2 years; 36% women; 6% nonwhite). Clinical strokes were detected in 17%, transient ischemic attack in 2%, and in-hospital mortality was 5%. The frequency of stroke in the Society for Thoracic Surgery database in this cohort was 7%. Most strokes were mild; the median National Institutes of Health Stroke Scale was 3 (interquartile range, 1–9). Clinical stroke was associated with increased length of stay (median, 12 versus 10 days; P =0.02). Moderate or severe stroke (National Institutes of Health Stroke Scale ≥10) occurred in 8 (4%) and was strongly associated with in-hospital mortality (38% versus 4%; P =0.005). Of the 109 stroke-free subjects with postoperative magnetic resonance imaging, silent infarct was identified in 59 (54%). Silent infarct was not associated with in-hospital mortality or increased length of stay. Conclusions— Clinical stroke after AVR was more common than reported previously, more than double for this same cohort in the Society for Thoracic Surgery database, and silent cerebral infarctions were detected in more than half of the patients undergoing AVR. Clinical stroke complicating AVR is associated with increased length of stay and mortality.
Mutations in BCKD-kinase Lead to a Potentially Treatable Form of Autism with Epilepsy
Novarino, Gaia , El-Fishawy, Paul, Kayserili, Hülya , Meguid, Nagwa A. , Scott, Eric , Schroth, Jana, Silhavy, Jennifer L., Kara, Majdi , Khalil, Rehab O., Ben‐Omran, Tawfeg , Ercan‐Sencicek, A. Gulhan , Hashish, Adel F. , Sanders, Stephan , Gupta, Abha R. , Hashem, Hebatalla S., Matern, Dietrich , Gabriel, Stacey , Sweetman, Larry, Rahimi, Yasmeen, Harris, Robert A. , State, Matthew W. , Gleeson, Joseph G. , Sanders, Stephan J

Mayo Clinic

Science | September 6, 2012 | Volume: 338 | Issue: 6105 | Pages: 394-397

10.1126/science.1224631 | PMID 22956686 Get It

A Fine Balance Intellectual and neurological disabilities can arise from diverse developmental aberrations. Novarino et al. (p. 394 , published online 6 September; see the Perspective by Beaudet ) have now determined the genetic basis for one such disorder for a small group of patients. Exome sequencing led to identification of mutations in a kinase BCKDK ( Branched Chain Ketoacid Dehydrogenase Kinase ) that regulates metabolism of branched-chain amino acids such as valine, leucine, and isoleucine. Mice with homozygous mutations in the BCKDK gene showed developmental and neurological abnormalities resembling those in certain mouse autism models. Analysis of transport mechanisms responsible for carrying amino acids across the blood-brain barrier revealed competition between the branched-chain amino acids and large neutral amino acids. Nutritional supplementation with extra branched-chain amino acids in the diet of mice carrying homozygous mutations in the BCKDK gene normalized their phenotype.
The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke
Pancioli, Arthur , Brott, Thomas G. , Tomsick, Thomas A. , Bean, Judy A., Zoppo, Gregory del, Kleindorfer, Dawn , Woo, Daniel , Khatri, Pooja , Castaldo, John , Frey, James L., Gebel, James, Kidwell, Chelsea S., Kwiatkowski, Thomas , Libman, Richard , Mackenzie, Richard S., Starkman, Sidney , Thurman, R. Jason, Jauch, Edward C. , Liebeskind, David S. , Meurer, William J. , Buck, Brian , Broderick, Joseph P. , Khoury, Jane , Kasner, Scott Eric , Scott, Phillip , Liebeskind, David S. , Buck, Brian H , Khatri, Pooja

Mayo Clinic

Stroke | September 5, 2008 | Volume: 39 | Issue: 12 | Pages: 3268-3276

10.1161/strokeaha.108.517656 | PMID 18772447 Get It

Background and Purpose— Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The c ombined approach to l ysis utilizing e ptifibatide a nd r ecombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination. Methods— The CLEAR trial was a National Institutes of Health/National Institute of Neurological Disorders and Stroke–funded multicenter, double-blind, randomized, dose-escalation and safety study. Patients were randomized 3:1 to either low-dose rt-PA (tier 1=0.3 mg/kg, tier 2=0.45 mg/kg) plus eptifibatide (75 μg/kg bolus followed by 0.75 μg/kg per min infusion for 2 hours) or standard-dose rt-PA (0.9 mg/kg). The primary safety end point was the incidence of symptomatic intracerebral hemorrhage within 36 hours. Secondary analyses were performed regarding clinical efficacy. Results— Ninety-four patients (40 in tier 1 and 54 in tier 2) were enrolled. The combination group of the 2 dose tiers (n=69) had a median age of 71 years and a median baseline National Institutes of Health Stroke Scale (NIHSS) score of 14, and the standard-dose rt-PA group (n=25) had a median age of 61 years and a median baseline NIHSS score of 10 ( P =0.01 for NIHSS score). Fifty-two (75%) of the combination treatment group and 24 (96%) of the standard treatment group had a baseline modified Rankin scale score of 0 ( P =0.04). There was 1 (1.4%; 95% CI, 0% to 4.3%) symptomatic intracranial hemorrhage in the combination group and 2 (8.0%; 95% CI, 0% to 19.2%) in the rt-PA–only arm ( P =0.17). During randomization in tier 2, a review by the independent data safety monitoring board demonstrated that the safety profile of combination therapy at the tier 2 doses was such that further enrollment was statistically unlikely to indicate inadequate safety for the combination treatment group, the ultimate outcome of the study. Thus, the study was halted. There was a trend toward increased clinical efficacy of standard-dose rt-PA compared with the combination treatment group. Conclusions— The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke.